ENVB has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ENVB has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Enveric Biosciences's PE Ratio without NRI is 0.00. Enveric Biosciences's 5-Year EBITDA growth rate is 53.10%. Therefore, Enveric Biosciences's PEG Ratio for today is 0.00.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Enveric Biosciences's PEG Ratio or its related term are showing as below:
During the past 13 years, Enveric Biosciences's highest PEG Ratio was 258.24. The lowest was 173.39. And the median was 221.76.
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
The historical data trend for Enveric Biosciences's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enveric Biosciences Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
PEG Ratio | Get a 7-Day Free Trial |
![]() |
![]() |
- | - | - | - | - |
Enveric Biosciences Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
PEG Ratio | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
- | - | - | - | - |
For the Biotechnology subindustry, Enveric Biosciences's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Enveric Biosciences's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Enveric Biosciences's PEG Ratio falls into.
PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.
Enveric Biosciences's PEG Ratio for today is calculated as
PEG Ratio | = | PE Ratio without NRI | / | 5-Year EBITDA Growth Rate* |
= | / | 53.10 | ||
= | 0.00 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Enveric Biosciences (NAS:ENVB) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Thank you for viewing the detailed overview of Enveric Biosciences's PEG Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Frank Pasqualone | director | 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080 |
Kevin Michael Coveney | officer: Chief Financial Officer | 10 CLEVELAND ST, A, SOMERVILLE MA 02143-2606 |
Robert Iv Dickey | officer: Chief Financial Officer | 320 WEST MERMAID LANE, PHILADELPHIA PA 19118 |
Bevin O'neil | director | C/O ENVERIC BIOSCIENCES, INC.,, 4851 TAMIAMI TRAIL N, SUITE 200, NAPLES FL 34103 |
Michael D Webb | director | C/O EPIX MEDICAL INC, 71 ROGERS ST, CAMBRIDGE MA 02142 |
Bradley George Thompson | director | 1646 ACTON AVE. SW, CALGARY, ALBERTA Z4 T2T 2P9 |
Jillian Marie Hagel | officer: Chief Technical Officer | 3655 36 ST NW, CALGARY, AB Z4 T2L 1Y8 |
Joseph Edward Tucker | director, officer: Chief Executive Officer | 3655 36 ST NW, CALGARY, AB, Z4 T2L 1Y8 |
Peter J. Facchini | officer: Chief Scientific Officer | 155 RANCHRIDGE DRIVE NW, CALGARY, ALBERTA Z4 T3G 1W1 |
Carter Julian Ward | officer: Chief Financial Officer | 165 LUDLOW AVE., NORTHVALE NJ 07647 |
Douglas Lind | director | |
Marcus Schabacker | director | ONE BAXTER PARKWAY, DEERFIELD IL 60015 |
Solomon Mayer | director | 150 CENTRAL PARK SOUTH 2ND FLOOR, NEW YORK NY 10019 |
David Ian Johnson | director, officer: CEO and Chairman | C/O ALLIQUA, INC., 850 3RD AVENUE, 18TH FLOOR, NEW YORK NY 10022 |
Robert G. Wilkins | officer: Chief Medical Officer | C/O JAY PHARMA INC., 4851 TAMIAMI TRAIL N, SUITE 200, NAPLES FL 34103 |
From GuruFocus
By Business Wire • 11-14-2024
By Faizan Farooque • 01-31-2025
By Business Wire • 11-25-2024
By Business Wire • 01-30-2025
By Business Wire • 02-03-2025
By Business Wire • 02-04-2025
By Business Wire • 01-06-2025
By Business Wire • 08-12-2024
By Business Wire • 01-06-2025
By Business Wire • 03-17-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.